Talazoparib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 638 publications

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Journal: Future oncology (London, England)

Published: June 09, 2026

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Journal: Molecular pharmaceutics

Published: June 08, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Journal: Future oncology (London, England)

Published: June 04, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives.

Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives.

Journal: Applied biochemistry and biotechnology

Published: May 02, 2026

Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine-benzimidazole hybrid as a potential dual-targeting anticancer agent.

Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine-benzimidazole hybrid as a potential dual-targeting anticancer agent.

Journal: Future medicinal chemistry

Published: April 22, 2026

Profile of Helen M. Piwnica-Worms.

Profile of Helen M. Piwnica-Worms.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 13, 2026

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 10, 2026

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Journal: RSC advances

Published: April 10, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

Journal: Biomedicines

Published: March 03, 2026

Showing 1-12 of 638

Last Updated: 06/30/2026